肾上腺髓质素(22-52 ),人
肾上腺髓质素(22-52 ),人结构式
|
常用名 | 肾上腺髓质素(22-52 ),人 | 英文名 | Adrenomedullin (22-52) (human) |
|---|---|---|---|---|
| CAS号 | 159899-65-7 | 分子量 | 3576.03 | |
| 密度 | N/A | 沸点 | N/A | |
| 分子式 | C159H252N46O48 | 熔点 | N/A | |
| MSDS | 美版 | 闪点 | N/A |
|
Adrenomedullin receptor binding sites in rat brain and peripheral tissues.
Eur. J. Pharmacol. 474 , 165-174, (2003) The existence of specific adrenomedullin receptor binding sites was investigated using the agonist peptide fragment [125I]human adrenomedullin-(13-52) in rat brain, lung and vas deferens homogenates. Saturation-binding experiments suggest that [125I]human adr... |
|
|
Adrenomedullin is anti-apoptotic in osteoblasts through CGRP1 receptors and MEK-ERK pathway.
J. Cell Physiol. 215 , 122-128, (2008) Adrenomedullin (ADM) has been shown to mediate multifunctional responses in cell culture and animal system such as regulation of growth and apoptosis. ADM stimulates the proliferation of osteoblasts in vitro and promotes bone growth in vivo. The ability of AD... |
|
|
Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis.
Oncogene 22 , 1238-1242, (2003) Since it is reported that adrenomedullin (AM) upregulated by hypoxia inhibits hypoxic cell death, we examined the effects of AM antagonist (AM C-terminal fragment; AM(22-52)) on the growth of pancreatic cancer cells. We, for the first time, demonstrated that ... |
|
|
Intermedin 1-53 inhibits rat cardiac fibroblast activation induced by angiotensin II.
Regul. Pept. 158 , 19-25, (2009) Intermedin (IMD) is a novel peptide related to calcitonin gene-related peptide (CGRP) and adrenomedullin (ADM). Proteolytic processing of a larger precursor of IMD yields a biologically active C-terminal fragment IMD(1-53). We aimed to observe the cardioprote... |
|
|
Effects of adrenomedullin and its fragment 22-52 on basal and ACTH-stimulated secretion of cultured rat adrenocortical cells.
Int. J. Mol. Med. 11 , 613-615, (2003) Adrenomedullin (ADM) and its receptors are expressed in the adrenal cortex, where ADM is currently known to inhibit agonist-stimulated aldosterone secretion from zona glomerulosa (ZG), without affecting either basal aldosterone release or the secretory activi... |